MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Guardant Health Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

106.78 -0.8

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

103.32

Max

108.25

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+15.92% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.2B

13B

Ankstesnė atidarymo kaina

107.58

Ankstesnė uždarymo kaina

106.78

Naujienos nuotaikos

By Acuity

50%

50%

173 / 370 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-12 23:54; UTC

Rinkos pokalbiai

CBA Could Underperform Again in 2026 -- Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2026-01-12 23:43; UTC

Rinkos pokalbiai

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026-01-12 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

2026-01-12 21:56; UTC

Rinkos pokalbiai

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

2026-01-12 20:54; UTC

Uždarbis

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

2026-01-12 20:48; UTC

Rinkos pokalbiai

Oil Futures Settle Higher in Choppy Trade -- Market Talk

2026-01-12 20:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

2026-01-12 19:39; UTC

Rinkos pokalbiai

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Gold and Silver Set New Records on Fed Probe -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 19:33; UTC

Rinkos pokalbiai

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

2026-01-12 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

2026-01-12 19:22; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

2026-01-12 18:21; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

2026-01-12 18:20; UTC

Įsigijimai, susijungimai, perėmimai

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

2026-01-12 18:19; UTC

Rinkos pokalbiai

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

2026-01-12 18:16; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Baidu's Outlook Bodes Well For Shares -- Market Talk

2026-01-12 18:01; UTC

Įsigijimai, susijungimai, perėmimai

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

2026-01-12 18:00; UTC

Rinkos pokalbiai

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

15.92% į viršų

12 mėnesių prognozė

Vidutinis 124.69 USD  15.92%

Aukščiausias 155 USD

Žemiausias 105 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

173 / 370 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat